FSD Pharma enters agreement with Ingenu CRO to conduct unbuzzd trial

FSD Pharma announced that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on February 19, 2024 to conduct “A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Safety and Efficacy of unbuzzd in Healthy Volunteers in an Induced State of Alcohol Intoxication. This trial is an important step to further verify that the effects of drinking unbuzzd helps a person sober up faster from the effects of alcohol. FSD Pharma’s proprietary dietary supplement product is called unbuzzd. unbuzzd is a fortified oral liquid formula that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism, and may accelerate the rate of alcohol metabolism in the body allowing a person to sober up faster. Celly Nu is the holder of exclusive rights to FSD Pharma’s technology for the recreational sale and use market. Separately FSD Pharma continues to develop a medical based product to accelerate the rate of alcohol metabolism for use in hospitals, medical centres and for front line workers.